The Covid vaccine no Aussies wanted

Deemed the “alternative” Covid vaccine, there were high hopes for Novavax in Australia when the more traditional formula got the tick of approval from the Therapeutic Goods Administration (TGA) in January. Due to its similar composition to hepatitis B, tetanus and diphtheria vaccines, a large amount of interest was shown for Novavax, or Nuvaxovid, by those who were reluctant to take either AstraZeneca, Pfizer or Moderna vaccines. Additionally experts, like TGA boss Adjunct Professor John Skerritt, believed the increased interest would see vaccination rates rise from 95 per cent fully vaccinated to at least 98 per cent. “I would have had several hundred emails from individuals and groups who have said for whatever reason we would like to have [this] particular vaccine … this just gives them further choice,” Professor Skerritt said upon Novavax’s approval in January.